[HTML][HTML] Regulation of PD-L1: a novel role of pro-survival signalling in cancer
Evasion of immune system is a hallmark of cancer, which enables cancer cells to escape the
attack from immune cells. Cancer cells can express many immune inhibitory signalling …
attack from immune cells. Cancer cells can express many immune inhibitory signalling …
Targeting EphA2 in cancer
T Xiao, Y Xiao, W Wang, YY Tang, Z Xiao… - Journal of hematology & …, 2020 - Springer
Eph receptors and the corresponding Eph receptor-interacting (ephrin) ligands jointly
constitute a critical cell signaling network that has multiple functions. The tyrosine kinase …
constitute a critical cell signaling network that has multiple functions. The tyrosine kinase …
Chimeric antigen receptors modified T-cells for cancer therapy
H Dai, Y Wang, X Lu, W Han - Journal of the National Cancer …, 2016 - academic.oup.com
The genetic modification and characterization of T-cells with chimeric antigen receptors
(CARs) allow functionally distinct T-cell subsets to recognize specific tumor cells. The …
(CARs) allow functionally distinct T-cell subsets to recognize specific tumor cells. The …
Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments
Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …
Principles and current clinical landscape of multispecific antibodies against cancer
M Elshiaty, H Schindler, P Christopoulos - International journal of …, 2021 - mdpi.com
Building upon the resounding therapeutic success of monoclonal antibodies, and supported
by accelerating progress in engineering methods, the field of multispecific therapeutic …
by accelerating progress in engineering methods, the field of multispecific therapeutic …
[HTML][HTML] Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: Simultaneous measurement of NF-κB, NFAT and AP-1
S Jutz, J Leitner, K Schmetterer, I Doel-Perez… - Journal of …, 2016 - Elsevier
Engagement of the T cell receptor complex reprograms T cells for proliferation, cytokine
production and differentiation towards effector cells. This process depends on activating …
production and differentiation towards effector cells. This process depends on activating …
Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas–FasL-Dependent AICD
A Künkele, AJ Johnson, LS Rolczynski… - Cancer immunology …, 2015 - AACR
Chimeric antigen receptor (CAR) development is biased toward selecting constructs that
elicit the highest magnitude of T-cell functional outputs. Here, we show that components of …
elicit the highest magnitude of T-cell functional outputs. Here, we show that components of …
CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia
Background Acute myeloid leukemia (AML) is one of the most common types of adult acute
leukemia. Standard chemotherapies can induce complete remission in selected patients; …
leukemia. Standard chemotherapies can induce complete remission in selected patients; …
Emerging CAR T cell strategies for the treatment of AML
P Vishwasrao, G Li, JC Boucher, DL Smith, SK Hui - Cancers, 2022 - mdpi.com
Simple Summary Chimeric antigen receptors (CARs) targeting CD19 have emerged as a
new treatment for hematological malignancies. As a “living therapy”, CARs can precisely …
new treatment for hematological malignancies. As a “living therapy”, CARs can precisely …
Current advances in T-cell-based cancer immunotherapy
Cancer is a leading cause of death worldwide; due to the lack of ideal cancer biomarkers for
early detection or diagnosis, most patients present with late-stage disease at the time of …
early detection or diagnosis, most patients present with late-stage disease at the time of …